AI-generated from publicly available materials.Cori Clinical, a London-based startup focused on streamlining clinical trials, has successfully secured €3.56 million ($4 million) in a Seed funding round led by Breega, with contributions from several other investors. This funding aims to enhance the company’s operational capacity, expand its team, and strengthen its regulatory and clinical intelligence capabilities.
The startup, co-founded by Jorn Jansen Schoonhoven and Patricio Fernández, offers a platform designed to consolidate fragmented data and insights from various clinical trials. This integrated approach allows clinical teams to make informed decisions, reducing the likelihood of costly delays caused by early design errors. Cori Clinical emphasizes the importance of a cohesive workspace that merges organizational knowledge with external data from regulatory bodies, creating a comprehensive resource for clinical and commercial teams alike.
Cori Clinical’s platform not only facilitates the transition from initial trial concepts to detailed operational plans but also adapts to evolving regulatory guidelines. By continuously updating its workspace with new information, the company aims to mitigate risks associated with trial design and execution. The potential impact of this innovation is significant; internal modeling suggests that it could lower trial setup costs by at least 33%, addressing a critical bottleneck in drug development.
This funding round positions Cori Clinical to expand its influence in the clinical development landscape, already collaborating with prominent enterprise CROs and academic institutions. As the company continues to refine its capabilities, it holds the promise of accelerating the clinical trial process, ultimately benefiting patients awaiting new treatments.